NASDAQ
No price data available for this timeframe.
Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company's IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the progra...
Apogee Therapeutics, Inc. (APGE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript...
Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic de...
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript...
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences....
Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key diff...
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic...
Blackstone (BX) is providing as much as $1.3 billion in financing to Apogee Therapeutics (APGE), giving the biotech company fresh capital to push zumilokibart t...
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt...
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H ...